In a direct compression platform for rosuvastatin calcium immediate-release tablets, the API is weighed as the calcium salt and corrected to the rosuvastatin free acid equivalent: 5.2 mg rosuvastatin calcium for a 5 mg dosage strength, 10.4 mg for 10 mg, 20.8 mg for 20 mg, and 41.6 mg for 40 mg. Direct compression is reserved for the lower three strengths at batch sizes exceeding 200,000 tablets. The API is screened through a 500 µm stainless steel sieve and pre-blended with colloidal silicon dioxide at 0.5–1.0 wt% and half of the microcrystalline cellulose NF in a 100 L bin blender operated at 8–12 rpm for 15 min. The pre-blend is charged with lactose monohydrate NF, crospovidone NF 2–4 wt%, and the remaining microcrystalline cellulose, then blended for an additional 15 min. Magnesium stearate NF is screened through a 250 µm screen, added at 0.5–1.0 wt%, and blended for 5 min. Compression is carried out on a rotary tablet press with B-tooling, 7 mm round flat-faced bevel-edge punches, compression force 6–14 kN, and turret speed 30–60 rpm. Core hardness is controlled at 40–80 N, friability is less than 1.0% after 100 revolutions per USP <1216>, and disintegration is complete within 15 min in water at 37°C per USP <701>. Dissolution is assessed by USP <711> Apparatus II at 50 rpm in 900 mL of 0.05 M sodium phosphate buffer at pH 6.6, with Q=80% released at 30 min. Aqueous hypromellose-based film coating is applied to a 3% weight gain, with inlet air at 60°C and exhaust air at 40–45°C. Residual solvents are controlled per USP <467>, elemental impurities per USP <232>/<233> and ICH Q3D Option 1, and content uniformity per USP <905> with acceptance value L1 ≤ 15.0.

Why Does Low Drug Loading Raise Blend Homogeneity Risk During Direct Compression?

At the 5 mg dose, rosuvastatin calcium 5.2 mg per tablet can represent only 4–6 wt% of a 90–120 mg core, and this low mass fraction creates segregation potential when the blend is discharged, transferred, or compressed. The critical release test under USP <905> requires acceptance value L1 ≤ 15.0 for single-dose samples, and process development usually targets a blend RSD below 3.0% for API assay. Production-scale bin blenders with free-fall mixing develop radial dead zones when fill volume falls below 40% or exceeds 80% of vessel capacity; batch size is therefore matched to the working volume rather than nominal capacity. A two-step pre-blend is used because direct addition of the micronic API to the main blend can leave API-rich pockets at hopper walls and bin surfaces. Particle-size distribution of the pre-blend is measured by laser diffraction per USP <429>; when the API d90 exceeds 25–30 µm or the particle aspect ratio exceeds 3:1, flow-induced segregation and dissolution lag at 30 min become more likely. Humidity is maintained at 40–50% RH because electrostatic charging of micronized API on stainless steel surfaces reduces mass flow and increases wall adhesion. Blend homogeneity monitoring by near-infrared spectroscopy at 5–8 min intervals provides real-time RSD trends, but release is confirmed by HPLC assay with individual unit results between 90.0% and 110.0% label claim. Lubrication time is capped because magnesium stearate at 0.5–1.0 wt% can hydrophobize the API surface if blended beyond 5–10 min, slowing dissolution in pH 6.6 phosphate buffer. If blend flow remains below the required index, a force feeder with paddle speed 20–40 rpm is used at the tablet press to prevent die-fill weight variation. The same controls apply to dust extraction lines because sub-10 µm API particles can accumulate in filters and create cross-contamination risk between batches.

Aqueous High-Shear Wet Granulation Route for the 40 mg Strength

High-shear wet granulation is selected for the 40 mg strength because direct compression of larger cores can produce capping at hardness values above 80 N and insufficient compactability at high press speed. In a top-drive high-shear granulator, rosuvastatin calcium 41.6 mg per tablet is dry-mixed with lactose monohydrate NF, microcrystalline cellulose pH 102, and croscarmellose sodium NF for 5 min at main impeller speed 300 rpm. Purified water containing 3–5 wt% povidone K30 or hypromellose 2910 5 mPa·s is added at 25–35 wt% of dry powder mass. Wet massing for 2–4 min at impeller speed 300–500 rpm and chopper speed 1500–2500 rpm generates granules with modal size 250–850 µm. Drying in a fluid-bed dryer uses inlet air at 55–60°C to a final loss on drying of 1.5–2.5 wt%; product temperature is kept below 45°C because prolonged thermal stress promotes lactone-related degradation impurity growth. Dried granules are milled through a 0.8–1.0 mm screen, blended with crospovidone 2–4 wt% and magnesium stearate 0.5–0.75 wt%, and compressed at 12–20 kN on a rotary press. Core hardness is 60–120 N, friability is below 0.5% after 100 revolutions per USP <1216>, and disintegration is complete within 15 min per USP <701>. Dissolution is tested in 900 mL of 0.05 M sodium phosphate buffer at pH 6.6 with USP <711> Apparatus II at 50 rpm, and the specification is Q=80% at 30 min. Aqueous hypromellose-based coating is applied to 3% weight gain with inlet air 60–65°C and exhaust air 40–45°C. Organic solvents are not required. Residual solvents per USP <467>, elemental impurities per USP <232>/<233> with ICH Q3D Option 1, and degradation products per ICH Q3B are compiled in the registration dossier. Process validation includes granule particle-size distribution, moisture content, bulk and tapped densities, compressibility index per USP <1174>, and content uniformity per USP <905>.

When encapsulation is selected as an alternative to tablet compression, rosuvastatin calcium is filled as a low-dose powder blend in hard gelatin or HPMC capsules. The API is screened through a 500 µm screen and pre-blended with sodium starch glycolate and one-third of the filler charge in a low-shear tumbler blender for 20 min at 10 rpm. The final blend contains 0.5–1.0 wt% sodium stearyl fumarate as lubricant, 2–4 wt% crospovidone as disintegrant, and filler selected from microcrystalline cellulose, pregelatinized starch, or mannitol. Equilibrium moisture content is held at 2.0–3.0 wt% and filling-room relative humidity at 40–45% to prevent electrostatic adhesion, powder bridging, and capsule shell plasticization. Automatic capsule fillers using dosator or tamping pin systems compress the powder into plugs and transfer them into size 3 or size 2 hard gelatin capsule bodies. Fill weight variation is monitored in-process, with an accepted RSD of ≤2.0% for 20 samples, and lock length is checked at line speed. Disintegration is tested per USP <701> in water at 37°C and must be complete within 15 min; dissolution is performed in 900 mL of 0.05 M sodium phosphate buffer at pH 6.6 with USP <711> Apparatus II at 50 rpm. Capsule shell cross-linking can occur if fill moisture exceeds 3.5 wt% or if storage temperature exceeds 40°C; failures after accelerated stability testing are often traced to pellicle formation in gelatin capsule shells. HPMC capsules with shell water content 3–7 wt% reduce cross-linking risk but require closer hopper humidity control because static charging increases at low RH. The encapsulated product is packaged in PVC/PVDC/aluminium blisters or HDPE bottles with desiccant, and stability studies follow ICH Q1A zones I–IV.

If Rosuvastatin Calcium Granules Are Filled into Sachets or Sprinkle Capsules

Granule presentations are not the default commercial form for rosuvastatin calcium, but they are occasionally developed for patients with swallowing difficulties or enteral administration. Wet granulation followed by fluid-bed drying is the dominant process; granule cores are built from rosuvastatin calcium, lactose monohydrate or mannitol, and hypromellose as binder. Extrusion-spheronization can produce pellets of 0.8–1.2 mm diameter, followed by functional coating with ethylcellulose 7 mPa·s and triethyl citrate as plasticizer to modulate release or mask taste. Dissolution of coated granules is evaluated by USP <711> in 0.05 M sodium phosphate buffer at pH 6.6; the 30-min release and lag time are strongly dependent on coating weight gain, with 5–10 wt% coating significantly slowing release. Moisture protection is critical because sachet presentations are exposed to humidity after opening; laminate material should have water vapor transmission rate below 0.001 g/m²/day and contain desiccant. Loss on drying after drying is set at 1.0–2.5 wt%, and the granule fraction between 500 µm and 150 µm should constitute at least 80% of total mass by sieve analysis. Taste-masking efficiency is screened by in vitro release at pH 5.5 and pH 6.6 to model oral cavity and intestinal segments. Published data for this specific rosuvastatin calcium sprinkle configuration is limited; formulation feasibility should be confirmed experimentally rather than assumed from tablet data. No pH-lowering enteric polymer is applied to rosuvastatin calcium without forced degradation verification, because acid exposure can promote lactonization and impurity formation.

Although oral solid dosage forms are the approved and pharmacopoeial route for rosuvastatin calcium, parenteral administration is an exploratory rather than compendial application. The calcium salt is only slightly soluble in water at neutral pH, so a simple aqueous solution for injection cannot reach the desired drug loading without solubilization. Solubilization strategies include co-solvent systems containing PEG 400 and propylene glycol, hydroxypropyl-beta-cyclodextrin complexation, or micellar carriers; however, hemolytic potential and precipitation upon dilution require explicit evaluation. If a sterile parenteral product were developed, USP <1> Injectable Products, USP <71> Sterility Tests, USP <85> Bacterial Endotoxins, and USP <788> Particulate Matter in Injections become mandatory, with endotoxin limit not more than 0.5 EU/mg unless justified by the maximum bolus dose. Terminal autoclaving at 121°C for 15 min is not assumed to be compatible; aseptic filtration through a 0.22 µm PVDF or PES membrane is more feasible if the formulation does not contain micronized particles. The process would require nitrogen sparging to limit oxidative degradation and possibly disodium edetate at 0.01–0.05 wt% as chelator. The degradation profile must be re-established because parenteral impurity thresholds differ from oral dosage forms; ICH Q3B and the rosuvastatin calcium oral monograph may not apply without parenteral-specific qualification. Published data for this specific configuration is limited; any injectable rosuvastatin calcium formulation must be treated as a separate development route with dedicated toxicology and stability modules.

Combining Rosuvastatin Calcium with Ezetimibe Requires Dry Granulation Before Final Blending

Fixed-dose combinations place rosuvastatin calcium in the same matrix as ezetimibe or fenofibric acid derivatives, and the process conflict shifts to chemical compatibility and dissolution fidelity. Ezetimibe is hydrophobic and poorly compressible, so dry granulation by roller compaction is used ahead of final blending; roll pressure 20–40 kN/cm and screen milling through 1.0 mm produce granules that preserve ezetimibe crystalline domains and reduce over-compaction. The rosuvastatin calcium component is added as a pre-blend with microcrystalline cellulose and crospovidone, then mixed with the ezetimibe granules. Lubrication is split between intragranular sodium stearyl fumarate and extragranular magnesium stearate to limit hydrophobization of both actives. Compression is performed on a rotary press at 12–22 kN, with hardness controlled at 60–110 N and friability below 0.5% per USP <1216>. Dissolution testing requires separate methods: rosuvastatin calcium is released in 0.05 M sodium phosphate buffer at pH 6.6 with USP <711> Apparatus II at 50 rpm, while the ezetimibe component typically requires a surfactant-containing medium because of its low aqueous solubility. Chromatographic assay is run with orthogonal HPLC conditions per USP <621>, and system suitability includes resolution between rosuvastatin calcium and its lactone impurity. Fenofibric acid combination data are less well documented; published fixed-dose data for some configurations is limited, and pH-modifying excipients must be tested for their effect on rosuvastatin calcium stability. Process validation includes two-dimensional chromatography, dissolution, content uniformity per USP <905>, and degradation product monitoring under ICH Q1A conditions.